［1］ GUAN Y F, BREYER M D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease［J］. Kidney Int, 2001, 60（1）: 14-30.
［2］ TORRA I P, CHINETT G, DUVAL C, et al. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice［J］.Curr Opin Lipidol, 2001, 12（3）: 245-254.
［3］ PATEL N S, DI PAOLA R, MAZZON E, et al. Peroxisome-proliferator activated receptor-{alpha} contributes to the resolution of inflammation following renal ischemia/reperfusion injury［J］.J Pharmacol Exp Ther, 2009, 328(2): 635-643.
［4］ NEGISHI K, NOIRI E, MAEDA R, et al. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury［J］.Kidney Int, 2008, 73(12): 1374-1384.
［5］ ZHOU Y, LUO P, CHANG H H, et al. Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension［J］.Kidney Int, 2008, 74(8): 1040-1048.
［6］ YOSHIOKA K, WAKINO S, HOMMA K, et al. Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats［J］.Obesity (Silver Spring), 2008, 16(5): 965-971.
［7］ ZHAO X, LI L Y. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats［J］.Am J Nephrol, 2008, 28(4): 598-606.
［8］ BANKS T, OYEKAN A. Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat［J］.J Hypertens, 2008, 26(3): 468-477.
［9］ DAVIDSON M H, ARMANI A, MCKENNEY J M, et al. Safety considerations with fibrate therapy［J］.Am J Cardiol, 2007, 99(6A): 3-18.
［10］ LEHMANN J M, LENHARD J M, OLIVER B B, et al. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs［J］.J Biol Chem, 1997, 272（6）: 3406-3410.
［11］ FIDALEO M , BERARDI E, SARTORI C. Differential modulation of PPARα and γ target gene expression in the liver and kidney of rats treated with aspirin［J］.Exp Toxicol Pathol, 2008, 59(6): 391-397.
［12］ NG V Y, HUANG Y, REDDY L M, et al. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha［J］.Drug Metab Dispos, 2007, 35(7): 1126-1134.
［13］ HSU Y H, CHEN C H, HOU C C, et al. Prostacyclin protects renal tubular cells from gentamicin-induced apoptosis via a PPARalpha-dependent pathway［J］.Kidney Int, 2008, 73(5): 578-587.
［14］ LIN H, HOU C C, CHENG C F, et al. Peroxisomal proliferator-activated receptor-alpha protects renal tubular cells from doxorubicin-induced apoptosis［J］.Mol Pharmacol, 2007, 72(5): 1238-1245.
［15］ MONDEN T, HOSOYA T, NAKAJIMA Y, et al. Herbal medicine, Hachimi-jio-gan, and its component cinnamomi cortex activate the peroxisome proliferator-activated receptor alpha in renal cells［J］.Endocr J, 2008, 55(3): 529-533.
［16］ DERLACZ R A, HYC K, USAREK M, et al. PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules［J］.Biochem Cell Biol, 2008, 86(5): 396-404.
［17］ WAKINO S, HAYASHI K, TATEMATSU S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats［J］.Hypertens Res, 2005, 28(3): 255-262.
［18］ ZHANG H, ZHANG A, KOHAN D E, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention［J］.Proc Natl Acad Sci USA, 2005,102(26):9406-9411.
［19］ YOUSEFIPOUR Z, HERCULE H, TRUONG L, et al. Ciglitazone, a peroxisome proliferator-activated receptor gamma inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure［J］.J Pharmacol Exp Ther, 2007, 322(2): 461-468.
［20］ EFRATI S, BERMAN S, ILGIYEAV E, et al. PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats［J］. Nephron Exp Nephrol, 2007, 106(4): 107-112.
［21］ QIN Y, LI X W, WEN Y B, et al. Effects of rosiglitazone on the expression connective tissue growth factor in tubulointerstitium in KKA(y) mice［J］.Acta Acad Med Sin（中国医学科学院学报），2006, 28(6):817-821.
［22］ WANG W, LIU F, CHEN N. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts［J］. Mediators Inflamm, 2007, 2007: 62641.doi：10.1155/2007/62641.
［23］ KAWAI T, MASAKI T, DOI S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduct ion of TGF-beta［J］.Lab Invest, 2009, 89(1): 47-58.
［24］ KO G J, KANG Y S, HAN S Y, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats［J］.Nephrol Dial Transplant, 2008, 23(9): 2750-2760.
［25］ SOMMER M, WOLF G. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide［J］.Am J Nephrol, 2007, 27(4): 425-434.
［26］ YOUSEFIPOUR Z, HERCULE H, OYEKAN A O, et al. Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPARgamma gene［J］.Ren Fail, 2007, 29(7): 903-910.
［27］ DOI S, MASAKI T, ARAKAWA T, et al. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury［J］.Transplantation, 2007, 84(2): 207-213.
［28］ WESTERWEEL P E, DEN OUDEN K, NGUYEN T Q, et al. Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing［J］. Am J Physiol Renal Physiol, 2008, 294(2): 379-384.
［29］ NAKANO R, KUROSAKI E, SHIMAYA A, et al. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction［J］.Eur J Pharmacol, 2006, 549(1-3): 185-191.
［30］ YAO Y, ZOU R, LIU X, et al. Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma［J］.J Huazhong Univ Sci Technolog （Med Sci）（华中科技大学学报：医学英德文）, 2008, 28(5): 543-548.
［31］ KIMURA H, LI X, TORII K, et al. A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions［J］.Nephrol Dial Transplant, 2008, 23(8): 2496-2503.
［32］ RASBACH K A, SCHNELLMANN R G. Isoflavones promote mitochondrial biogenesis［J］.J Pharmacol Exp Ther, 2008, 325(2): 536-543.
［33］ ZHANG H, ZHANG A, KOHAN D E, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention［J］.Proc Natl Acad Sci USA, 2005, 102（26）:9406 -9411.
［34］ MARCEILLE J R, GOINS J A, SONI R, et al. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin［J］.Pharmacotherapy, 2004, 24（10）:1317-1322.
［35］ SCHEEN A J. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? ［J］. Drug Saf, 2004,27（12）: 841-856.
［36］ ARTUNC F, SANDULACHE D, NASIR O, et al. Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone［J］.Pflugers Arch, 2008, 456(2): 425-436.
［37］ GIRAL H, VILLA-BELLOSTA R, CATALáN J, et al. Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines［J］.Toxicol In Vitro, 2007, 21(6):1066-1076.
［38］ GILDE A J, FRUCHART J C, STAELS B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease［J］.J Am Coll Cardiol, 2006, 48(9 suppl A): 24-32.
［39］ GROSS B, STAELS B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes［J］.Best Prac Res Clin Endocrinol Metab, 2007, 21(4): 687-710.
［40］ BAILEY C J. Learning from tesaglitazar［J］.Diabetes Vasc Dis Res, 2007, 4(3): 161-162.